Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma

Jeong, Shin Ok; Kim, Eui Bae; Jeong, Soung Won; Jang, Jae Young; Lee, Sae Hwan; Kim, Sang Gyune; Woo, Sang Myung; Kim, Young Seok; Cho, Young Deok; Kim, Hong Soo; Kim, Boo Sung; Kim, Yong Jae; Goo, Dong Erk; Park, Suyeon

doi:10.5009/gnl16001

Cited by 59 publications

(47 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fi ndings of the present study demonstrated an inverse association between tumor number and DFS time following initial TACE. Consistent with the present study, several previous studies have identified tumor number as a predictor of intrahepatic recurrence following initial TACE for HCC (27)(28)(29)(30)(31). Recurrence following initial remission by TACE has been more often reported in patients with multinodular-type HCC and with portal vein thrombosis (32).…”

Section: Discussionsupporting

confidence: 79%

Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization

et al. 2017

View full text Add to dashboard Cite

Abstract. Hepatocellular carcinoma (HCC) is prone to recurrence following curative treatment. The purpose of the present study was to identify the predisposing factors of HCC recurrence following complete remission achieved by transarterial chemoembolization (TACE). A retrospective cohort study of 70 consecutive patients with HCC who underwent TACE as the initial treatment was conducted. The patients were divided into two groups according to their 1-year disease-free survival (DFS) status; the early recurrence group (ER group; n=32), with HCC recurring within 1 year of initial TACE; and the non-early recurrence group (NER group; n=38), who did not experience recurrence within 1 year. The parameters identified as significantly associated with DFS time on univariate analysis were aspartate aminotransferase (AST), alanine aminotransferase and α-fetoprotein levels, as well as the tumor number (P=0.003, P=0.027, P=0.002 and P=0.005, respectively). Multivariate analysis revealed that AST levels and tumor number were significantly associated with a shorter DFS period (P=0.009 and P=0.038, respectively). The Mantel-Haenszel test revealed a significant trend of decreasing DFS with increasing tumor number. Among the patients with HCC in the ER group, locoregional recurrence occurred more frequently in those who received TACE alone compared with those treated with TACE combined with radiofrequency ablation treatment. In summary, multinodularity of HCC is the most potent predictive factor for the recurrence of HCC within 1 year of initial TACE.

show abstract

Section: Discussionsupporting

confidence: 79%

Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization

et al. 2017

View full text Add to dashboard Cite

show abstract

“…While surgical resection and local ablative therapies are considered curative, recurrence rates approach 25%‐35% within the first year and 50%‐60% within 2 years . Further, up to 25%‐50% of patients in some studies received TACE, which is typically not curative and associated with a high risk of recurrence . Further, patients with high‐risk tumour characteristics (eg, multifocal HCC or elevated AFP) have higher recurrence rates than their counterparts; however, specific data regarding these risk factors and subgroup analyses were not reported in many studies.…”

Section: Discussionmentioning

confidence: 99%

Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy

Saraiya

Yopp

Rich

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Jeong et al [25] reported that 28.2% of patients with various stages of HCC who underwent TACE showed a complete response after treatment. Another study showed that 6 months after treatment for BCLC stage B/C HCCs, the overall response rate was 12.50% in the sorafenib monotherapy group and 18.75% in the TACE + sorafenib group [26].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study

et al. 2018

View full text Add to dashboard Cite

Aim: We analyzed the effectiveness of external particle radiotherapy (PRT) as an alternative therapy for various stages of hepatocellular carcinoma (HCC). Methods: Eighty-three patients with HCC underwent PRT in our hospital from 2007 to 2015 (proton beam radiation in 58 patients and carbon ion radiation in 25 patients), including patients with early-stage HCC (single HCC measuring ≤3 cm, Barcelona Clinic Liver Cancer [BCLC] stage 0 or A) (group A, n = 30), those with intermediate-stage HCC (HCCs measuring ≥3 cm but inoperable or multinodular and transcatheter arterial embolization [TACE]-refractory, BCLC stage B) (group B, n = 31), and those with advanced-stage HCC (HCC with portal invasion or extrahepatic metastasis) (group C, n = 22). The median radiation dose was 72.6 GyE (range 50–74) for proton beam radiation and 45.0 GyE (range 45–52.8) for carbon beam radiation. Local control ability was defined as continuous shrinkage of the tumor size without development of new lesions for ≥6 months after PRT. Results: The rates of local control of the target tumor at 6 months, 1 year, and 2 years were 91.9, 86.3, and 84.8%, respectively. The overall survival rates at 1, 2, and 3 years were 83.0, 65.6, and 55.1%, respectively. Patients in group A showed the best survival rates (100.0% at 1 year and 85.9% at 2 years). The 1-year survival rate was poor in group C (63.6%) despite a good local tumor control rate of 74.7%. The overall survival rates were significantly better in groups A and B than in group C. Conclusions: The local control rates after PRT were sufficiently high compared to TACE or sorafenib. Thus, PRT should be adopted for patients with difficult-to-treat HCC in the early and intermediate stages.

show abstract

Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma

Cited by 59 publications

References 28 publications

Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization

Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization

Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy

Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study

Contact Info

Product

Resources

About